One Lantern, Three Destinations! 3.2 Million Fans Follow IN XI'AN to Discover a City Where Ancient Meets Modern

One Lantern, Three Destinations! 3.2 Million Fans Follow IN XI'AN to Discover a City Where Ancient Meets Modern

XI'AN, China, Oct. 28, 2025 /PRNewswire/ -- In August 2025, Xi'an's overseas social media account IN XI'AN launched the special campaign "One Light, One Journey," focusing on cultural resonance across Chinatowns in San Francisco, London, and Milan....

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis Interim safety and pharmacokinetic data from healthy volunteers anticipated in 2H...

menu
menu